Clinical Research Directory
Browse clinical research sites, groups, and studies.
Itraconazole Therapy In Bronchiectasis With Airway Mold
Sponsor: Mayo Clinic
Summary
The primary objective of this study is to evaluate the feasibility of itraconazole therapy in patients with bronchiectasis and airway mold. Feasibility will be assessed through recruitment success, treatment adherence, tolerability, and participant retention. The study will also explore the impact on respiratory symptoms and airway microbiome diversity.
Official title: Itraconazole Therapy In Bronchiectasis With Airway Mold: A Single-Arm Pilot Trial Of Feasibility, Safety, And Impact On Respiratory Symptoms And Airway Microbiome Diversity
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2026-03-15
Completion Date
2030-12-31
Last Updated
2026-02-10
Healthy Volunteers
No
Interventions
Itraconazole 200 mg
Subjects will receive oral itraconazole, 200 mg twice daily, for six weeks, based on prior dosing regimens for airway fungal disease.
Locations (1)
Mayo Clinic in Rochester
Rochester, Minnesota, United States